Humacyte (NASDAQ:HUMA - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at D. Boral Capital in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $25.00 target price on the stock.
Several other equities research analysts have also weighed in on the company. Benchmark reiterated a "buy" rating on shares of Humacyte in a research note on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and issued a $15.00 price target (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $13.71.
View Our Latest Research Report on Humacyte
Humacyte Price Performance
Shares of Humacyte stock traded up $0.10 during trading on Friday, hitting $3.00. 1,744,361 shares of the company's stock traded hands, compared to its average volume of 2,276,819. Humacyte has a twelve month low of $2.81 and a twelve month high of $9.97. The company has a market cap of $377.58 million, a PE ratio of -2.24 and a beta of 1.36. The firm's fifty day moving average price is $4.09 and its 200 day moving average price is $4.77.
Hedge Funds Weigh In On Humacyte
A number of large investors have recently modified their holdings of the stock. Vontobel Holding Ltd. acquired a new stake in shares of Humacyte in the fourth quarter valued at approximately $50,000. Petros Family Wealth LLC bought a new position in Humacyte in the 4th quarter valued at $50,000. Syon Capital LLC acquired a new stake in shares of Humacyte in the 4th quarter valued at $54,000. Brookstone Capital Management bought a new stake in shares of Humacyte during the fourth quarter worth $56,000. Finally, ACT Wealth Management LLC acquired a new position in shares of Humacyte during the fourth quarter valued at $57,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.
Humacyte Company Profile
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Further Reading
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
